Feasibility and Safety of Allogeneic Adipose Mesenchymal Stem Cells (aMSCs) Delivery Into Kidney Allografts Procured From Deceased Donors With High Kidney Donor Profile Index (KDPI)

Feasibility and Safety of Allogeneic Adipose Mesenchymal Stem Cells (aMSCs) Delivery Into Kidney Allografts Procured From Deceased Donors With High Kidney Donor Profile Index (KDPI)

The purpose of this research is to test an investigational drug called Adipose Mesenchymal Stem Cells (aMSCs) for the treatment of ischemia re-perfusion injury (IRI) in patients that have had a kidney transplant.

Inclusion Criteria:

• Male or female kidney transplant candidates age 18 and above.
• Patient is receiving kidney allograft from deceased donor with KDPI>85%.
• Ability of subject to give appropriate consent.
• Females of childbearing potential with agreement to use birth control for six months post-transplant.
• Approved by the Mayo Clinic Transplant Selection Committee.
• Signed Authorization for Donation of Anatomical Gifts on file.

Exclusion Criteria:

• Positive pregnancy test at the time of the kidney offer is called for the potential recipient.
• Kidney transplant potential recipients with active malignancy (except none melanoma skin malignancies).
• Patients with previous history of solid organ transplant (Heart, Lung, Intestine, Kidney and/or Pancreas).
• Patients with previous history of bone marrow transplant.